Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medpharmics LLC

Neither a doctor nor a teaching hospital

Research payments

$23,441,828

3,821 payments

Through program year 2025, Medpharmics LLC is reported as receiving $23,441,828 in research payments, across 3,821 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $38,995 5
2024 Research $448,378 358
2023 Research $1,762,812 370
2022 Research $7,342,778 1,397
2021 Research $7,225,987 905
2020 Research $4,575,401 507
2019 Research $2,047,477 279

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $13,576,521 1,184 payments
  2. GlaxoSmithKline, LLC. $5,256,914 1,566 payments
  3. Seqirus USA Inc $1,054,420 710 payments
  4. Moderna TX, Inc. $843,995 90 payments
  5. Genentech, Inc. $819,543 25 payments
  6. Novavax Inc $524,153 75 payments
  7. Abbott Laboratories $501,353 13 payments
  8. Boston Scientific Corporation $299,861 50 payments
  9. BioNTech SE $213,603 42 payments
  10. Ventana Medical Systems, Inc. $157,579 24 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $6,871,447 429 payments
  2. A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women $2,005,803 112 payments
  3. Study name not reported $1,758,180 527 payments
  4. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,685,956 65 payments
  5. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr $991,517 430 payments
  6. Phase 3B, Randomized, Observer-Blind. Multicenter Study to Assess the $715,452 180 payments
  7. RSV Mat-004 $641,850 126 payments
  8. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $606,097 51 payments
  9. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $562,453 147 payments
  10. Phii Il22fc Anti St2 in Severe Covid 19 Pneumonia $559,853 13 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $36,615 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record